12:00 AM
 | 
Oct 11, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Macimorelin: Interim Phase III data

Interim data from an open-label, crossover, U.S. Phase III trial in 42 patients with confirmed AGHD or multiple pituitary hormone deficiencies and 10 healthy volunteers showed that growth hormone stimulation with oral AEZS-130 had 95% sensitivity and 90% specificity for identifying patients who should receive therapy for AGHD vs. 86% sensitivity and 90% specificity with the previous standard diagnostic test consisting of IV...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >